Therefore, limited resources should be directed to source control first, because ineffective pest control will compromise all the other more expensive interventions. The first step in cockroach control is determining if cockroaches are present and where aggregations are located. This is best implemented with a combined thorough visual inspection for live cockroaches and signs of infestation and the overnight use of multiple sticky traps throughout the home. Some studies use only two or three traps in the kitchen, and this approach can easily miss substantial aggregations of cockroaches elsewhere in the home. However, allergen levels may still be significant without obvious presence of live cockroaches, and measurement of allergen levels provides an estimate of exposure and the need for abatement. Specific enzyme-linked immunoassays for Bla g 1 and Bla g 2 are used to monitor environmental cockroach exposure [36,95]. The goal is to keep contaminant exposure below threshold levels for adverse health effects (see Section 15. Cockroaches can be controlled using a variety of insecticides formulated as baits, dusts, sprays, and aerosols. Organochlorine, organophosphate, and carbamate insecticides, which were extensively used in sprays against cockroaches, are no longer registered with the U. However, their use is not recommended in most residential settings because they deposit residues that may be contacted by children and pets. Moreover, most populations of the German cockroach are highly resistant to pyrethroid insecticides, significantly compromising their effectiveness. Effective dusts include boric acid and diatomaceous earth (silica), but their use requires some skill, and they are often applied excessively and in improper locations. Biological approaches to environmental control are being researched but are still far from being commercially developed. The effectiveness of pest control in reducing cockroaches and allergens is significantly influenced by the tactics used in the intervention. Gel baits are without a doubt the most effective and safest chemical approach in cockroach control. Their effectiveness stems from several biological, ecological, and toxicological characteristics: (1) Insecticides, like pharmaceuticals, are generally more bioavailable and effective by ingestion than by dermal contact. Finally, (10) cockroaches engage in coprophagy (ingestion of feces within an aggregation) and other social feeding behaviors, so unmetabolized insecticide in their feces can kill other cockroaches within the resting aggregation. The availability of effective baits has revolutionized cockroach control and dramatically increased the effectiveness of interventions and allergen reduction. Cockroach population reductions of 95%­100% are common when baits are properly deployed and multiple sticky traps are used during the intervention to guide bait placement, determine amount, assess efficacy, and steer further actions [10,110,112]. Although baits have been shown to be highly effective, and cockroach control alone can significantly reduce cockroach allergens in infested homes [110,113], an integrated intervention should include cleaning, vacuuming, making repairs to eliminate water and hiding places, and improving sanitation (Table 15. The extent of cockroach allergen stability and allergen persistence in the environment following cockroach eradication measures is unknown, so thorough cleaning and vacuuming are especially recommended after cockroaches have been eliminated to remove cockroach allergen found in feces, cast cuticles, and body parts from the environment. An ongoing debate in the environmental intervention community is the relative effectiveness of single interventions, designed to reduce a major pest. A recent review of single and multicomponent interventions concluded that results of both approaches are variable, and we know little about the contribution of specific approaches to multicomponent interventions [114]. A central concern, not addressed in this report, is how the effectiveness of environmental interventions is assessed, whether cockroach populations were monitored, and the durability and sustainability of the home-based intervention. Most interventions either subcontract the cockroach control to a pest control company or provide residents the tools to implement their own pest control; in both cases, little detail is disclosed on how the intervention was conducted and which and how much insecticide used. Personal experience, as well as a blinded study [112], demonstrate that these approaches frequently fail to reduce cockroach infestations in low-income communities. Moreover, most reports neither objectively assess nor report the effectiveness of cockroach control, often relying on resident or pest control technician testimonials instead of the standard unbiased use of multiple sticky traps. Because extensive allergen reduction can be accomplished only after cockroaches are substantially reduced or eradicated, the relative effectiveness of single and multicomponent interventions can Table 15. Chemical measures-Direct cockroach eradication Note: All sprays and aerosols of organochlorine (chlordane), organophosphate (chlorpyrifos, diazinon, propetamphos), and carbamate (bendiocarb, propoxur) insecticides were banned by the U. Baits (gels, pastes, granules, stations): abamectin, boric acid, clothianidin, dinotefuran, emamectin benzoate, fipronil, hydramethylon, indoxacarb, and pyriproxifen. Most gel baits are highly effective if properly placed in many small dots near cockroach hiding places. There is some evidence of physiologic and behavioral resistance to baits, but both can be minimized and mitigated with rotations among baits with different modes of action. Isolate and seal the refuse/garbage bin Salient points 251 be adequately assessed only when cockroach control has been shown to be highly effective using objective and unbiased assessment tools. However, sustained decrease of cockroach allergens was difficult to achieve, and the levels, in this and other studies, remained above those reported to be clinically significant (reviewed in [95]). As pointed out by Gore and Schal, because the effectiveness of the cockroach intervention was not assessed, it is possible that live cockroaches continued to disseminate allergens in the dormitory rooms. Moreover, the relative contribution of the two interventions (pest control, cleaning) could not be discerned in this and many other multicomponent interventions. This early example of a cockroach intervention that is not sufficiently characterized is typical of many subsequent interventions. Some recent studies aiming to document that reduction in exposure can be associated with improvement in disease have begun to monitor cockroach populations to assess the effectiveness of the intervention, but two important shortcomings remain. First, some studies report extremely low baseline cockroach populations and low allergen levels, so the quantification of further pest reduction would require greater sensitivity (lower limit of detection) that can only be achieved with more traps placed in critical locations. Second, some recent pest interventions have adopted "integrated pest management" but with no further details on the specific tactics and intensity of each intervention. This oversight constitutes a significant barrier for transparent and unbiased critical assessment of the intervention. The availability of effective baits (discussed earlier in this section) has dramatically changed cockroach interventions. Given the high efficacy of properly implemented bait treatments, it is important to note several inadequacies in how they are treated in some reviews, meta-analyses, and even policy decisions [114,117]. First, pest control interventions that target different pests are often grouped as "multicomponent interventions," with the tacit expectation of equivalent outcomes with all pests. In fact, acaricides targeting house dust mites are not nearly as effective as baits targeting cockroaches, and it is nearly impossible to eradicate mite populations with pesticides alone. It is not surprising therefore that acaricidebased interventions have contributed little to allergen reductions and clinical outcomes. Second, the requirements in randomized controlled trials of blinding participants and study personnel, and of placebo controls, severely limit the number of studies included in reviews and meta-analyses. The requirement for randomized controlled trials, in itself, disqualifies many excellent entomological interventions on the effectiveness of innovative tactics for cockroach control. Blinding participants is clearly required when they are the target of the intervention. But the target of cockroach interventions is the pest population, not participants, and blinding, while useful, is neither practical nor useful if unbiased assessment tools. Finally, placebo treatments with baits lacking insecticide are ill-advised, because they supplement the home environment with highly palatable cockroach food that can unintentionally increase the pest population. Despite limited evidence, cockroach eradication and reduced exposure to cockroach allergens in infested structures could lead to improvements in asthma morbidity among cockroach-sensitized patients [108,116], reviewed by Gore et al. In urban and inner-city areas, up to 80% of children with asthma may have IgE antibody to cockroach allergens. Infestations of domiciliary cockroaches are largely dependent on housing conditions. The average American spends approximately 95% of time indoors in controlled environments that lead to continued low-dose allergen exposure, which may lead to sensitization in predisposed individuals. Amorphous cockroach particles containing allergens are recognized as an important source of indoor allergens, together with dust mite particles. Cross-reactivity of arthropod allergens can be identified among members of the taxonomic groups Crustacea, Arachnida, and Insecta, described as "pan-allergy. Molecular cloning of cockroach and other insect allergens has provided the basis for investigating the relationship between allergen function/structure and allergenicity. Currently, cockroach immunotherapy is based on the use of nonstandardized allergens with variable allergen content. Recombinant cockroach allergens are potential new tools for the future diagnosis and treatment of cockroach hypersensitivity. The x-ray crystal structures of Bla g 2 alone and in combination with fragments of antibodies that interfere with IgE antibody binding revealed molecular features that contribute to allergenicity and antigenic determinants for design of hypoallergens. Eradication of cockroaches and other insect infestations is essential to control inhalant insect allergic diseases. The composition of environmental dust includes a wide range of components from the biosystem, and given the widespread distribution of insects in the world, their involvement in allergic reactions will continue to be of major social, economic, and medical importance. Future directions for research should include the study of cockroach reduction strategies, development of specific assays to detect clinically relevant insect inhalant allergens, and measures to reduce exposure to environmental allergens (including patient education for pest management and the safe use of insecticides and nontoxic traps). Helm for his contributions to cockroach allergy research and to previous versions of the chapter that evolved into the present one. Part of the research described in this chapter was supported by Indoor Biotechnologies, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Housing and Urban Development. Arthropods and invertebrates allergy (with the exclusion of mites): the concept of panallergy. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. Inner city asthma study: Relationships among sensitivity, allergen exposure, and asthma morbidity. A comparative study of prevalence of skin hypersensitivity to cockroach and house dust antigens. Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. The role of indoor allergen sensitization and exposure in causing morbidity in women with asthma. Repeatedly high polycyclic aromatic hydrocarbon exposure and cockroach sensitization among inner-city children. Cockroach exposure independent of sensitization status and association with hospitalizations for asthma in inner-city children. Lack of association between indoor allergen sensitization and asthma morbidity in inner-city adults. Overlapping community compositions of gut and fecal microbiomes in labreared and field-collected German cockroaches. Insects in confined swine operations carry a large antibiotic resistant and potentially virulent enterococcal community. Dust and airborne exposure to allergens derived from cockroach (Blattella germanica) in low-cost public housing in Strasbourg (France). The novel structure of the cockroach allergen Bla g 1 has implications for allergenicity and exposure assessment. Mite, cat, and cockroach exposure, allergen sensitisation, and asthma in children: A case-control study of three schools. Relationship of indoor allergen exposure to skin test sensitivity in inner-city children with asthma. Anticockroach and anti-mouse IgE are associated with early wheeze and atopy in an inner-city birth cohort. Sensitization to Per a 2 of the American cockroach correlates with more clinical severity among airway allergic patients in Taiwan. Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity. The genomic and functional landscapes of developmental plasticity in the American cockroach. Identification and purification of an important cross-reactive allergen from American (Periplaneta americana) and German (Blattella germanica) cockroach. Identification, quantitation, and purification of cockroach allergens using monoclonal antibodies. Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity. Novel allergen structures with tandem amino acid repeats derived from German and American cockroach. Molecular cloning of Per a 1 and definition of the crossreactive Group 1 cockroach allergens. Gene expression and tissue distribution of the major human allergen Bla g 1 in the German cockroach, Blattella germanica L. Expression, production and excretion of Bla g 1, a major human allergen, in relation to food intake in the German cockroach, Blattella germanica. Specific IgE and IgG antibody-binding patterns to recombinant cockroach allergens. Crystal structure of cockroach allergen Bla g 2, an unusual zinc binding aspartic protease with a novel mode of self-inhibition. Cockroach allergen Bla g 2: Structure, function, and implications for allergic sensitization. Intrinsic properties of allergens and environmental exposure as determinants of allergenicity. Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody. Carbohydrates contribute to the interactions between cockroach allergen Bla g 2 and a monoclonal antibody.

Additional information:

• Raloxifene
• Atenolol

Most of the commercial dog dander extracts contain very low levels of Can f 1; however, the acetone precipitated (A-P) dog 1:100 w/v manufactured by Hollister-Stier contains an average of 140 µg/mL Can f 1. A study, similar in design to those conducted with cat extract by Ewbank and Nanda, compared the response to Hollister-Stier A-P dog vaccine containing 0. The conclusion was that the greatest and most consistent response was seen with a dose of dog extract containing 15 µg of Can f 1. The doseresponse study by Haugaard [28] demonstrated that there was marginal reduction in bronchial reactivity to mite allergen after 2 years of treatment with a maximum dose containing 0. This treatment also reduced conjunctival sensitivity and the late skin test response to timothy grass extract. Dolz treated allergic subjects for 3 years with a vaccine containing 15 µg/injection of the major allergens of a grass mixture [38]. There was a progressive decrease in ocular, nasal, and pulmonary symptoms over the 3 years of the study. Compared to placebo, symptom and medication scores during the peak pollen season were reduced 32% and 41% in the high-dose cohort versus 19% and 14% in those on the low dose. Based on multiple allergen extracts from multiple companies manufactured in the United States provided in footnotes a and c. Based on multiple lots of extracts manufactured by a single manufacturer between 2001 and 2011. Studies at Johns Hopkins have included both single and multiple maintenance doses. However, the dose studies have involved either progressively increasing doses in the same individuals or administering different doses for a different number of years. There have been no studies in which groups of subjects receive different maximum doses for the same duration of treatment. Nevertheless, the data show that clinical and objective benefits occur within months and are maintained with maximum maintenance doses containing 11 µg [42] to 24. If, as is most often true in the United States, the patient is to receive a mixture of unrelated extracts, then (1) utilization of allergenic relationships and crossallergenicity to achieve similar effective doses for non-cross-reacting and cross-reacting allergens; (2) avoidance of a combination of extracts that will degrade other components; and (3) selection of the type of diluent become important considerations. It is possible to estimate the amount of each extract that should be added to the maintenance vial in order to deliver an effective dose from this information (Table 26. It is best to use the mean value in the absence of specific information on the major allergen content of a specific vial (Table 26. To formulate a 10 mL maintenance vaccine, the effective dose expressed as its major allergen content is multiplied by 20. This amount is then divided by the major allergen content per milliliter in the concentrated extract to give the amount of the concentrated extract to be added to the maintenance vial. Representative amounts of the standardized extracts to be added to a 10 mL maintenance vial are provided in Table 26. What of the majority of allergens for which there is no information about optimal doses and no standardized extracts Limited data on major allergen content of nonstandardized pollen extracts suggests a range of major allergen content similar to that of standardized pollens (Table 26. The amount for the two house dust mite extracts is reduced to one-half to allow for significant cross-allergenicity; if only one is used, the amount should be doubled. Major allergen content will vary from lot to lot from the same manufacturer and among different manufacturers for extracts of the same labeled potency. Based on multiple allergen extracts manufactured by multiple companies in the United States as cited in footnotes a and c. Extract Birch, Olive, Oak Sage Kochia* Russian thistle* Giant ragweed Concentration 1:10 w/v 1:10 w/v 1:10 w/v 1:10 w/v 1:10 w/v 26. Each should be treated as a separate allergen group, using either timothy or a mixture for the northern pasture grasses for one and Bermuda for the other. If more than one member of each of these subfamilies of grasses is to be included in a vaccine, the amount of each grass should be reduced to compensate for the marked cross-allergenicity. There are also some regional grasses such as Bahia and Johnson that are in distinct subfamilies (Table 26. Although they share some allergenicity with the northern pasture grasses, if locally important, they should be added as an additional component of the vaccine. Note: the final concentration for each nonstandardized allergen group is approximately 1:100 w/v. Those extracts marked with an (*) are included in reduced amounts to compensate for significant crossallergenicity [31]. The rationale for a target of 1:100 w/v or a 10-fold dilution from the strongest available stock extract is by analogy with clinical studies on standardized ragweed [7]. Representative amounts of some nonstandardized extracts to be added to a 10 mL maintenance vial are given in Table 26. This reflects the high degree of cross-allergenicity between these two species of Dermatophagoides. Cross-allergenicity among closely related plant pollen is also the rule (see Table 26. If these relationships are not recognized, an allergen vaccine may contain excessive amounts of some groups of allergens. This is most likely to occur with the grasses, since most of the prevalent species in the United States fall into two non-cross-reacting botanical subfamilies [55]: northern pasture grasses typified by timothy and Bermuda and related grasses. Other important cross-reacting groups are the individual members of the Ambrosia subtribe; the Artemisia genus; the Chenopod-Amaranth families of weeds; and members of certain tree groups, such as the genus Populus containing aspen, poplar, and cottonwood species, and the junipers and cedars of the family Cupressaceae [55]. Hazelnut Hornbeam Olive Family [57]: European olive Ash Privet Russian olive (unrelated) Cupressaceae (cypress) Family [55]: Cedar Cypress Juniper Arbor vitae Fagaceae Family [55] Table 26. There is generally a degree of cross-allergenicity between tribes or genera of a family, but this is variable. There is generally a high degree of cross-allergenicity between species of the same genus. Beech-oak Genus Carya [55] Pecan-hickory Genus Populus [55] Poplar-aspen-cottonwood 26. Eragrostoideae: Bermuda grass, grama, several western prairie grasses Pancoideae: Bahia, Johnson 26. Two are in the Composite family, the Ambrosia, which includes the ragweeds and related species, and the Artemisia, which includes the sages, wormwoods, and mugworts. The Chenopod-Amaranth families include many of the prominent weeds of the Western United States. The major ragweeds (short, giant, and western) are strongly cross-reactive, and an experimental Amb a 1 extract inhibited the binding of serum sIgE to the three major and seven minor ragweed species by 98%­100% suggesting strong crossreactivity [58]. The locally most important of the three major ragweeds or a mixture should be used for treatment. There is no clinically important cross-allergenicity of the ragweeds with other members of the Ambrosia tribe, such as cocklebur and burweed, nor is there significant cross-reactivity between ragweeds and the other clinically significant group in the Composite family, the Artemisia [59]. Within the Artemisia, however, there is strong cross-reactivity, and one representative species should suffice for treatment [59]. The Chenopod-Amaranth families, which share some allergenicity, are best viewed as three groups: the Atriplex and the Amaranths, both of which are strongly cross-reactive, and the Chenopods, which share some allergens. Locally important weeds such as sorrel, dock, and plantain should be treated as distinct allergens [55]. The house dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae, are strongly crossreactive [60]. A mix of both major species is probably best employed if both are locally important. Extracts of a number of fungi (molds) and insects contain proteases that are capable of degrading allergenic proteins in other extracts with which they may be mixed in a vaccine [63­66] (Table 26. Major allergens in American cockroach and house dust mites are gut derived and very likely are digestive enzymes [63,67]. Note: the extract listed in the first column was mixed with perennial ryegrass extract and stored at 4°C for 1 month. The potency of a 10-fold dilution of timothy grass stored under differing conditions was compared by enzyme-linked immunosorbent assay inhibition to that of a freshly diluted aliquot. After 3 months, the diluted timothy extract had a significant decrease in potency compared to the fresh. In addition, those aliquots of timothy stored in combination with Alternaria, cockroach, and the mixture of Alternaria, Cladosporium, Penicillium, and cockroach all showed significantly greater loss of potency than the timothy extract stored alone. Detectable trypsin-like proteolytic activity is absent from extracts derived from animal dander and pollen [63] (Table 26. Alternaria significantly reduced the potency of five of eight extracts, cockroach reduced the potency of three of eight, and Cladosporium reduced the potency of only one extract. Cladosporium and cockroach reduced the potency of some extracts that were not affected by Alternaria. Furthermore, the effect of Alternaria extracts was inconsistent from lot to lot, suggesting varying quantities of protease activity were present in different lots of Alternaria extract [68]. The extracts that have been shown to have deleterious effects on the potency of other extracts include Alternaria [68,69], Cladosporium [68,69], cockroach [65,68,69], Helminthosporium [65], Penicillium [63,69], Aspergillus [63,69], Fusarium [66], Bipolaris [69], and Epicoccum [69]. This possibly results from their having low protease activity and having been tested in a diluent containing glycerin [68,69]. While no single inhibitor will protect against all proteases [64], glycerin has been shown to have protective effects against some [63,69]. After 3 months, the residual allergenic activity of the reference allergen extract in the mixes was compared to that of the same extract stored alone. The p value is the overall difference among the seven conditions of storage (alone and six different combinations with other allergenic extracts). A (+) indicates significant degradation of the reference allergen extract due to mixing. Mixing Alternaria extract with several other fungal extracts did not cause loss of potency, and mixing cockroach and imported fire ant extracts did not cause loss of potency. However, mixing Alternaria extract with insect extracts or German cockroach extract with fungal extracts, even in 10%­ 25% glycerin, led to marked loss of some allergens in both extracts [70]. Similar results are reported with mixing Aspergillus and other fungal extracts with American cockroach [71]. The most effective preservation of extract integrity and potency is not by adding a preservative but by lyophilization [72,73]. This is not routinely employed because the lyophilization process adds to the cost of the extracts. Serum control 0 Ragweed 3-month Alternaria Fresh Ragweed 3-month with: Cladosporium Peniciillium Cockroach D. The potency of a 10-fold dilution of short ragweed stored under differing conditions was compared by enzyme-linked immunosorbent assay inhibition to that of a freshly diluted aliquot. After 3 months, the diluted short ragweed extract and those aliquots of ragweed stored in combination with Alternaria, Penicillium, Cladosporium, and cockroach alone and in combination were all equal in potency to the freshly diluted aliquot of short ragweed. At this concentration, it inhibits some but not all proteolytic enzymes [63,66,73]. This may contribute to but does not completely explain its effectiveness as a preservative. Decreasing effectiveness of glycerin as a preservative occurs with 25% and 10% concentrations of glycerin [69,74,75]. It is possible that the presence of glycerin accounts for the lack of proteolytic degradation of pollen extracts by the house dust mite extracts in several mixing studies [65,68,69]. Over 50% of timothy grass extract potency was lost within 3 days of being mixed with Fusarium [66]. Birch pollen lost 70% of its allergenic potency over a period of 60 days when mixed with Fusarium [66]. Some allergenic activity always remains, suggesting that not all allergens in these extracts are susceptible to proteolytic digestion. On mixing with Fusarium, Bet v 6 and Phl p 5 were almost entirely degraded, while Bet v 1 and Phl p 1 remained relatively stable [66]. However, even though there may be a significant amount of overall allergenic activity remaining, the selective reduction in certain allergens will make the vaccine less suitable for treatment and may place the patient at risk when being treated with a freshly prepared vaccine that contains allergens no longer present in the mix that they had been receiving for immunotherapy. The results of testing of the effects of mixing extracts is not always consistent. Thus, ragweed is reported to be resistant [66] and susceptible [69] and cat dander susceptible [68] and resistant [69] when mixed with Fusarium. These differing results may reflect the marked variability in the composition of fungal and cockroach extracts and differing methods of assessing loss of potency. In summary, many pollen and animal dander extracts are susceptible to accelerated loss of potency when mixed in a vaccine with protease containing extracts. Despite the variable reports, the safest practice is to not include pollen and dander extracts in a vaccine with cockroach or fungal extracts. House dust mite extracts in 10% glycerin appear to be neither susceptible to exogenous proteases nor to cause loss of potency due to their protease content [68,69]. Human serum albumin does not have protective effects against proteolytic enzymes [63]. Phenol denatures proteins, including those in allergen extracts [72], and the deleterious effect of phenol increases with greater allergen dilutions [74]. Siliconization of vials has been suggested to decrease adsorption of proteins to their surface. In the absence of preservatives, extracts stored in saline buffered with bicarbonate lost potency to a greater extent than those stored in phosphate-buffered saline or normal saline [73,75]. The processes that lead to loss of vaccine potency and the measures that can be used to reduce the effect are listed in Table 26. Loss of activity with storage at room temperatures is likely caused by the proteases [72], while loss of potency with brief exposure to higher temperatures is probably related to heat lability of some of the allergenic proteins [81]. Some extracts, such as cat [79], are relatively resistant to this thermal lability effect.

Cheese Fruit (Morinda). Accupril.

• Are there any interactions with medications?
• Colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, nausea, smallpox, enlarged spleen, kidney disorders, swelling, asthma, bone and joint problems, cancer, eye cataracts, colds, depression, digestion problems, stomach ulcers, heart trouble, high blood pressure, infections, migraine, stroke, pain, reducing signs of aging, and other conditions.
• Are there safety concerns?
• What is Noni?
• How does Noni work?
• Dosing considerations for Noni.

Source: http://www.rxlist.com/script/main/art.asp?articlekey=96740

Moreover, respiratory sensitization to cat epithelium containing Fel d 2 may lead to pork-cat syndrome in which IgE crossreactivity between albumins leads to hypersensitivity symptoms upon ingestion of pork meat containing pork albumin [167]. This IgE cross-reactive glycan, present in cat Fel d 5w (IgA), can also interfere with the cat dander-specific IgE measurements of parasiteinfected individuals [85]. The guidelines are straightforward for persons already sensitized to mammalian allergens. Avoidance, or reduction of exposure when total avoidance is not possible, is the primary strategy to prevent or to reduce allergic symptoms. Mammalian pet allergen concentrations in homes with pets are 10 to 100 times higher than in homes without pets. Removing the pet from the household results in a gradual reduction of the allergen levels. In practice, families often wish to keep their pets for emotional reasons, and various measures have been proposed to reduce the exposure in these circumstances. Although a reduction in the allergen levels can be achieved, the beneficial effect on health is not straightforward. The measurement of allergen concentrations in dust samples may help to evaluate the efficacy of control measures [8]. As the first line of prevention against laboratory animal allergy, persons with an atopic background, especially if they are already allergic to animals, should be discouraged from engaging in these jobs [176]. Personal protection against occupational exposure should be used when appropriate. Planning of tasks to reduce stable intermediate-level exposure might help to reduce sensitization [17]. Preventive measures include the reduction of airborne allergen levels within laboratory animal facilities. Ideally, a comprehensive plan should be utilized, starting from the appropriate design of the facilities and ventilation system. The use of curtains in front of cage racks or filter-topped animal cages reduce the dispersion of rodent allergens in the animal room. In one study, individually ventilated cage systems decreased ambient rodent allergen levels 250-fold or more under optimal conditions. Automated cage-handling machines reduce the exposure to persons emptying and cleaning soiled cages. The most effective personal protection against airborne allergens is achieved with ventilated, motorized helmets in which inhaled air is pumped through type P2 or P3 filters. Although somewhat inconvenient to use, the helmet enables asthmatic persons to work safely with animals. Mammalian respiratory allergens are primarily dispersed in dander, saliva, and urine. Exposure to mammalian allergens is not limited to immediate contact with animals; these allergens are commonly present in indoor environments. Almost all important mammalian aeroallergens belong to the lipocalin family of proteins. Environmental control measures can help symptomatic individuals, although complete avoidance of exposure is preferable. Both mammalian serum albumins and lipocalin allergens exhibit IgE cross-reactivity. It is conceivable that avoiding contact with pets would restrain sensitization and the clinical manifestations of allergy. However, several studies suggest a protective effect of a high-level exposure to cat and dog-derived dust early in childhood [170­173]. IgE antibodies to animalderived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma. Relevance of specific IgE antibody titer to the prevalence, severity, and persistence of asthma among 19-year-olds in northern Sweden. Allergy to lipocalins: A consequence of misguided T-cell recognition of self and nonself Severe childhood asthma and allergy to furry animals: Refined assessment using molecular-based allergy diagnostics. Molecular allergy diagnostics refine characterization of children sensitized to dog dander. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: A population-based cross-sectional study. Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen. Evolution of the IgE and IgG repertoire to a comprehensive array of allergen molecules in the first decade of life. Both the variability and level of mouse allergen exposure influence the phenotype of the immune response in workers at a mouse facility. The lipocalin protein family: Protein sequence, structure and relationship to the calycin superfamily. T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. Mammal-derived respiratory lipocalin allergens do not exhibit dendritic cell-activating capacity. Allergenic Can f 1 and its human homologue Lcn-1 direct dendritic cells to induce divergent immune responses. Lipopolysaccharideenhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. Recognition of the major cat allergen Fel d 1 through the cysteine-rich domain of the mannose receptor determines its allergenicity. The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes. Probing the mechanisms of low immunogenicity of a lipocalin allergen, Bos d 2, in a mouse model. Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells. Structural differences between human proteins and aero- and microbial allergens define allergenicity. Allergen and epitope targets of mouse-specific T cell responses in allergy and asthma. Escherichia coli expression and purification of recombinant dog albumin, a cross-reactive animal allergen. Sensitization to minor cat allergen components is associated with type-2 biomarkers in young asthmatics. A population-based study of animal component sensitization, asthma, and rhinitis in schoolchildren. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. IgE and IgG binding patterns and T-cell recognition of Fel d 1 and non-Fel d 1 cat allergens. Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. Determination of isoforms, N-linked glycan structure and disulfide bond linkages of the major cat allergen Fel d1 by a mass spectrometric approach. Expression and genomic structure of the genes encoding FdI, the major allergen from the domestic cat. Structural characterization of the tetrameric form of the major cat allergen Fel d 1. Immunological differences in the global release of the major cat allergen Fel d 1 are influenced by sex and behaviour. Studies on the biochemical structure of the major cat allergen Felis domesticus I. IgE epitopes on the cat (Felis domesticus) major allergen Fel d I-A study with overlapping synthetic peptides. Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Molecular cloning, expression and modelling of cat allergen, cystatin (Fel d 3), a cysteine protease inhibitor. Populationbased study of multiplexed IgE sensitization in relation to asthma, exhaled nitric oxide, and bronchial responsiveness. Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-1,3galactose. Two newly identified cat allergens: the von Ebner gland protein Fel d 7 and the latherin-like protein Fel d 8. The cat lipocalin Fel d 7 and its cross-reactivity with the dog lipocalin Can f 1. The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: Cloning and immunological characterization of the recombinant forms. Assessment of recombinant dog allergens Can f 1 and Can f 2 for the diagnosis of dog allergy. Crystal structure of the dog lipocalin allergen Can f 2: Implications for cross-reactivity to the cat allergen Fel d 4. Affinity purification of a major and a minor allergen from dog extract: Serologic 94. Environmental exposure to allergens of different dog breeds and relevance in allergological diagnostics. Can f 1 levels in hair and homes of different dog breeds: Lack of evidence to describe any dog breed as hypoallergenic. Molecular and immunological characterization of Can f 4: A dog dander allergen cross-reactive with a 23 kDa odorant-binding protein in cow dander. Structural aspects of dog allergies: the crystal structure of a dog dander allergen Can f 4. Characterization of the dog lipocalin allergen Can f 6: the role in cross-reactivity with cat and horse. Identification of a new major dog allergen highly cross-reactive with Fel d 4 in a population of cat- and dog-sensitized patients. Canis familiaris allergen Can f 6: Expression, purification and analysis of B-cell epitopes in Chinese dog allergic children. Crystal structure of the allergen Equ c 1-A dimeric lipocalin with restricted IgE-reactive epitopes. Separation of horse dander allergen proteins by twodimensional electrophoresis-Molecular characterisation and identification of Equ c 2. IgG and IgE antibody responses to cow dander and urine in farmers with cowinduced asthma. Homology of a bovine allergen and the oligomycin sensitivity-conferring protein of the mitochondrial adenosine triphosphate synthase complex. Immunologic and biochemical properties of the major mouse urinary allergen (Mus m 1). Expression of a lipocalin in Pichia pastoris: Secretion, purification and binding activity of a recombinant mouse major urinary protein. Occupational asthma and rhinitis related to laboratory rats: Serum IgG and IgE antibodies to the rat urinary allergen. Purification and partial characterization of the major allergen, Cav p 1, from guinea pig Cavia porcellus. Evaluation of two new recombinant guinea-pig lipocalins, Cav p 2 and Cav p 3, in the diagnosis of guinea-pig allergy. Identification and isolation of a Fel d 1-like molecule as a major rabbit allergen. Male-specific submaxillary gland protein, a lipocalin allergen of the golden hamster, differs from the lipocalin allergens of Siberian and Roborovski dwarf hamsters. Molecular and immunological characterization of the first allergenic lipocalin in hamster: the major allergen from Siberian hamster (Phodopus sungorus). Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. Characterization of a novel isoform of -nascent polypeptide-associated complex as IgE-defined autoantigen. Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity. Immunological and structural analysis of IgE-mediated cross-reactivity between manganese superoxide dismutases. Humoral and cellmediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to Aspergillus fumigatus P2 protein. Detection of an allergen in dog dander that cross-reacts with the major cat allergen, Fel d 1. Dual sensitization to rat and mouse urinary allergens reflects cross-reactive molecules rather than atopy. A comparison of Can f 1 with Can f 2 regarding their biochemical and immunological properties.

Usage: p.c.

The assay was successfully performed in 104 patients (87%), and a ToO was assigned in 63 patients (61%). In the remaining 41 patients (39%), the molecular profiles were not specific for the 6 primary tumor types assigned by this assay. The ToOs most commonly identified were lung, pancreas, and colon; most of these patients had clinical and pathologic features consistent with these diagnoses. Monzon and colleagues described a multicenter validation of a 1550-gene expression profile for identification of tumor ToO. Performance within the subgroup of metastatic cancers was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup. This signature was applied to an independent, published data set of 170 samples, and prediction was established in 86% of the metastatic cases. The assay result was consistent or compatible with the clinicopathological features, and a putative primary cancer could be assigned in 84% of cases processed successfully. The assay was performed on formalin-fixed, paraffinembedded biopsy specimens in a blinded fashion, and the assay results were compared with clinicopathologic data and the actual latent primary sites. Of 289 patients enrolled, 252 had successful assays performed, and 247 (98%) had a ToO predicted. The sites most commonly predicted were the biliary tract (18%), urothelium (11%), colorectal (10%), and non­small cell lung cancer (7%). A total of 223 patients were treatment candidates, and 194 patients received assay-directed, sitespecific treatment. When the assay predicted tumor types that were clinically more responsive, the median survival time was significantly improved compared with predictions of more resistant tumors (13. A recent study reported that epigenetic profiling may be one additional method for identifying the putative primary cancer. Across the cancer spectrum, ongoing histology and cellular-context agnostic prospective clinical trials are studying the utility of using actionable mutations and total mutational burden to match patients to a targeted drug or immunotherapeutic. Although systemic chemotherapy is the main treatment modality in most patients, the careful integration of surgery, radiation therapy, and even periods of observation are important in the overall management of these individuals. Favorable Clinical Subsets Squamous Carcinoma Involving Mid-High Cervical Lymph Nodes High cervical adenopathy with squamous cell carcinoma has been mentioned previously because of its well-defined natural history, high frequency of identification of the primary site, and responsiveness to therapy. When no primary site is found, aggressive local therapy is applied to the involved neck. A potential advantage of radiation therapy is that the suspected primary anatomic sites (nasopharynx, oropharynx, and hypopharynx) can be included in the radiation port. However, one randomized study in 1989 suggested that chemotherapy with cisplatin and 5-fluorouracil improved the response rate and median survival rate compared with radiation alone. Adenocarcinoma involving mid-high cervical nodes and lower cervical or supraclavicular adenopathy of all histologic types carries a much poorer prognosis. These patients are managed with radiation therapy, or more often, they may be candidates for systemic cytotoxic therapies. Women With Isolated Axillary Adenopathy Isolated axillary adenopathy secondary to metastatic adenocarcinoma usually occurs in women and has unique clinical features. In this setting, adequate immunohistochemistry to evaluate the potential for occult breast cancer is essential. However, a reported series of 42 patients suggested that the survival rate was superior in patients receiving systemic chemotherapy, and local control was improved by irradiating the breast and axilla. The actuarial disease-free survival rate in this study was 71% at 5 years and 65% at 10 years. The management of patients with involvement of the axilla as well as other sites or nonadenocarcinoma histology is less certain. These patients usually are approached by using a combination of local and systemic modalities, and pathologic evaluation drives the management. Combination chemotherapy regimens specific for germ cell carcinoma of testicular origin were used in the treatment of these patients. In selected patients, these regimens have produced documented complete responses and an actual 10-year disease-free survival rate of 16%. Poorly Differentiated Neuroendocrine Carcinoma Poorly differentiated neuroendocrine carcinoma is a clinicopathological entity recognized primarily for its responsiveness to therapy. There probably is considerable overlap with extrapulmonary small cell carcinomas, anaplastic carcinoid, anaplastic islet cell tumors, Merkel cell tumors, and paragangliomas. Histologically, these tumors are very poorly differentiated, but histochemical stains are positive for chromogranin or neuron-specific enolase. These patients often are seen with diffuse hepatic or bone metastases but do not have the indolent histologic or clinical features of typical carcinoid tumors, islet cell tumors, or paragangliomas, and thus observation is not appropriate. In selected patients, this can result in a prolonged disease-free survival period and even a cure, with outcomes clearly influenced by the tumor lineage and biology. In patients with a known primary, colon cancer patients do better with upfront surgery, but patients with pancreatic cancer may benefit from preoperative chemotherapy. Women With Serous Papillary Peritoneal Carcinomatosis Women with diffuse (serous) peritoneal carcinomatosis with adenocarcinoma make up another recognized subset. These patients form a distinctive subset because of their clinical similarities to patients with ovarian carcinoma. Numerous authors have recognized this patient subset, terming this syndrome peritoneal papillary serous carcinoma or multifocal extraovarian serous carcinoma. In one study, many patients underwent exploratory laparotomy with surgical debulking followed by chemotherapy. For unselected patients, numerous empiric chemotherapy combinations have been reported. Response rates generally range from 20% to 30%, but most responses are partial and brief, resulting in little impact on median survival. The median progression-free survival time was 6 months, with a median survival time for the entire group of 9 months. This study showed that combination chemotherapy with gemcitabine, carboplatin, and paclitaxel followed by weekly paclitaxel was well tolerated. Another study reported on gemcitabine and oxaliplatin front line result with similar outcomes. Changing Status of Therapeutics for Carcinoma of Unknown Primary the combination therapy trials discussed in this chapter have made a significant contribution in the post­5-fluorouracil and cisplatin era of second-generation chemotherapeutic agents. In appropriate patients, assessment of biomarkers that may be associated with a specific therapeutic intervention should be strongly considered. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. Use of cytokeratin, 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Identification of occult breast lesions detected by magnetic resonance imaging with targeted ultrasound: a prospective study. The role of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies [published online February 12, 2015]. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. Investiga, tion and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. Clinical outcomes of patients with metastatic carcinomas of unknown primary presenting with peritoneal carcinomatosis [abstract]. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. Retinoblastoma Nonrhabdomyosarcoma Soft Tissue Sarcoma · Amongpersonsyoungerthan20 years,6. Solid tumors account for 60% of all pediatric malignant neoplasms, with approximately 3700 new cases diagnosed each year in the United States. The spectrum of tumor types that occur in children is much different from that observed in adults. Enormous progress has been made in the diagnosis and management of these tumors since the original demonstration of the chemosensitivity of Wilms tumor to actinomycin D in 1966. Cure rates for most childhood solid tumors have increased by as much as 50% since the mid-1970s. The increase is attributable largely to improved understanding of prognostically important biological and clinical features, enhanced precision of clinical staging systems, consistent use of supportive care, and development of more effective treatment, often incorporating a combination of chemotherapy, surgery, and radiation therapy. Several observations support the association between skeletal growth velocity and osteosarcoma. First, patients with osteosarcoma tend to be taller than their counterparts without this disease. Second, osteosarcoma develops at an earlier age in female patients than in male patients, perhaps because of differences in the timing of onset of puberty and the growth spurt. In a study involving 91 patients with second malignant bone sarcomas, osteosarcoma accounted for 72 cases, 52 (72%) of these tumors arising within previously irradiated fields. Osteosarcoma as a second malignancy is often associated with retinoblastoma; osteosarcoma is the most common malignancy in survivors of retinoblastoma, both in the irradiated and the nonirradiated areas, and it accounts for 25% to 40% of all second neoplasms in this population. Studies using next-generation sequencing technologies show multiple somatic chromosomal lesions, including structural variations and copy number alterations. Conventional osteosarcoma can be subdivided histologically into three major groups depending on the predominant cell type. Approximately 50% of tumors are categorized as osteoblastic because the predominant extracellular element is osteoid, but 25% are chondroblastic, with a prominent cartilaginous component. Approximately 25% have a herringbone pattern similar to that observed in fibrosarcoma and are therefore called fibroblastic. No significant differences in overall outcome are apparent among these three histologic subtypes. Characteristic radiologic findings in osteosarcoma commonly include a metaphyseal permeative lesion with periosteal new bone formation and destruction of preexisting cortical bone. A baseline chest radiograph should be obtained to search for distant metastatic lesions. Angiography usually is reserved for patients who receive intraarterial chemotherapy or for those who need optimal vessel visualization before limb salvage. The tumor may be easily palpable when located in areas such as the anterior surface of the femur but may manifest only as leg edema when occurring in difficult-to-appreciate areas such as the popliteal fossa. A painful limp that increases with weight bearing is the third most common symptom. Osteosarcoma most commonly involves the long bones, most tumors occurring around the knee. The most frequent sites of involvement are the distal part of the femur, the proximal portion of the tibia, and the proximal part of the humerus. The axial skeleton, including the pelvis, is rarely affected in children (<10% of cases) but more frequently is involved in patients older than 60 years. The latter appears to correlate with osteoblastic activity and thus has proved useful in monitoring response to therapy. Overall, the radiographic appearance is not that of a typical osteosarcoma, which usually has a mixture of blastic and lytic areas. Indeed, a purely lytic radiographic appearance is a diagnostic requirement for its diagnosis. Microscopically, this tumor consists of cystlike spaces divided by septa, which are composed of highly atypical sarcomatous tissue. Unlike aneurysmal bone cysts, these cystic spaces have no endothelial lining, and the tumor cells are in direct contact with areas of hemorrhage. With appropriate multimodality therapy, however, the outcome is similar to or better than that for conventional osteosarcoma. Its anatomic distribution is similar to that of conventional osteosarcoma, with predilection for the distal femur and proximal tibia. In contrast with conventional osteosarcoma, symptoms typically develop over many months or even years before the patient comes to medical attention.